TRACON Pharmaceuticals Inc (TCON) Stock Price and Analyst Predictions

The stock has a 36-month beta value of 1.04. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”

The public float for TCON is 40.26M, and at present, short sellers hold a 4.71% of that float. On April 03, 2024, the average trading volume of TCON was 2.98M shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

TCON) stock’s latest price update

TRACON Pharmaceuticals Inc (NASDAQ: TCON)’s stock price has plunge by -25.43relation to previous closing price of 0.42. Nevertheless, the company has seen a -27.93% plunge in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-02-28 that SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2023 financial and operating results after the close of U.S. financial markets on Tuesday, March 5, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

TCON’s Market Performance

TRACON Pharmaceuticals Inc (TCON) has seen a -27.93% fall in stock performance for the week, with a 64.40% gain in the past month and a 75.08% surge in the past quarter. The volatility ratio for the week is 11.70%, and the volatility levels for the past 30 days are at 25.38% for TCON. The simple moving average for the past 20 days is -18.02% for TCON’s stock, with a 29.86% simple moving average for the past 200 days.

Analysts’ Opinion of TCON

Many brokerage firms have already submitted their reports for TCON stocks, with BTIG Research repeating the rating for TCON by listing it as a “Buy.” The predicted price for TCON in the upcoming period, according to BTIG Research is $14 based on the research report published on April 16, 2021 of the previous year 2021.

Maxim Group, on the other hand, stated in their research note that they expect to see TCON reach a price target of $24. The rating they have provided for TCON stocks is “Buy” according to the report published on February 10th, 2021.

H.C. Wainwright gave a rating of “Buy” to TCON, setting the target price at $18 in the report published on December 23rd of the previous year.

TCON Trading at 17.42% from the 50-Day Moving Average

After a stumble in the market that brought TCON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.52% of loss for the given period.

Volatility was left at 25.38%, however, over the last 30 days, the volatility rate increased by 11.70%, as shares surge +65.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +98.65% upper at present.

During the last 5 trading sessions, TCON fell by -27.93%, which changed the moving average for the period of 200-days by -39.01% in comparison to the 20-day moving average, which settled at $0.3841. In addition, TRACON Pharmaceuticals Inc saw 76.98% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TCON starting from THEUER CHARLES, who purchase 47,000 shares at the price of $0.75 back on Apr 27 ’23. After this action, THEUER CHARLES now owns 399,417 shares of TRACON Pharmaceuticals Inc, valued at $35,250 using the latest closing price.

THEUER CHARLES, the President and CEO of TRACON Pharmaceuticals Inc, purchase 3,999 shares at $0.66 during a trade that took place back on Apr 26 ’23, which means that THEUER CHARLES is holding 352,417 shares at $2,639 based on the most recent closing price.

Stock Fundamentals for TCON

Current profitability levels for the company are sitting at:

  • -0.77 for the present operating margin
  • 1.0 for the gross margin

The net margin for TRACON Pharmaceuticals Inc stands at -0.5. The total capital return value is set at 120.43.

Based on TRACON Pharmaceuticals Inc (TCON), the company’s capital structure generated -0.41 points at debt to capital in total, while cash flow to debt ratio is standing at 15.58. The debt to equity ratio resting at -0.29. The interest coverage ratio of the stock is 1.85.

Currently, EBITDA for the company is -6.88 million with net debt to EBITDA at 0.85. When we switch over and look at the enterprise to sales, we see a ratio of 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.89.

Conclusion

To sum up, TRACON Pharmaceuticals Inc (TCON) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts